14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
CLYM vs PTN: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Climb Bio, Inc. (CLYM) captures the overall head-to-head institutional edge over Palatin Technologies, Inc. (PTN) on higher Unified Composite conviction (45.7/100 HOLD vs. 31.5/100 SELL) after splitting the core matrix 7–3 (led by Growth & Scale, Profitability & Quality), while PTN wins 3–2 across the 6-pillar growth and valuation breakdown. CLYM trades at $9.94 (N/M Forward P/E, 0.0% operating margin) versus PTN at $6.12 (42.9x Forward P/E, -65.7% operating margin).
Growth vs. Quality Trade-Off: CLYM earns the overall head-to-head edge with a stronger Unified Composite Score (45.7/100 HOLD vs. PTN 31.5/100 SELL) and 1.50β · 114% Vol risk profile, whereas PTN leads top-line expansion (-80.1% YoY revenue growth, 1.62x PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
Technical & Structure Timing Caution: CLYM trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 45.2); meanwhile PTN is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 44.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CLYM vs PTN. Trailing 12-month operating profitability (CLYM 0.0% vs PTN -65.7%) and valuation multiples (CLYM N/M vs PTN 42.9x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $11.1M market capitalization and -65.7% operating margin.
OpEx & R&D Reinvestment71.9% of Rev ($9.5M)
90D Engineering Disclosures0 Published
Investor FAQ CLYM vs PTN Key Questions & Quantitative Answers
As of Nov 16, 2026, Climb Bio, Inc. (CLYM) captures the overall head-to-head institutional edge over Palatin Technologies, Inc. (PTN) on higher Unified Composite conviction (45.7/100 HOLD vs. 31.5/100 SELL) after splitting the core matrix 7–3 (led by Growth & Scale, Profitability & Quality), while PTN wins 3–2 across the 6-pillar growth and valuation breakdown. CLYM trades at $9.94 (N/M Forward P/E, 0.0% operating margin) versus PTN at $6.12 (42.9x Forward P/E, -65.7% operating margin). Growth vs. Quality Trade-Off: CLYM earns the overall head-to-head edge with a stronger Unified Composite Score (45.7/100 HOLD vs. PTN 31.5/100 SELL) and 1.50β · 114% Vol risk profile, whereas PTN leads top-line expansion (-80.1% YoY revenue growth, 1.62x PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: CLYM trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 45.2); meanwhile PTN is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 44.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
CLYM leads the Growth & Scale pillar: CLYM posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with PTN at -80.1% YoY revenue growth and +0.0% YoY earnings growth on $13M TTM revenue (6.2% gross margin, -65.7% operating margin). On trailing 12-month operating scale, CLYM generates N/A in USD-normalized revenue versus $13M for PTN. In operating R&D and SG&A reinvestment, CLYM deploys N/A (0 90-day corporate R&D disclosures) versus 71.9% of Rev ($9.5M) (0 disclosures) for PTN.
PTN screens cheaper on headline valuation multiples. CLYM trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas PTN trades at 42.9x Forward P/E, 42.9x Trailing P/E, 1.62x PEG, and 0.1x EV/Revenue (-113.6% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CLYM (-29.3% ROE) versus PTN (-877.5% ROE) capital efficiency.
In options market volatility and institutional positioning, CLYM carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.50β · 114% Vol realized risk). By comparison, PTN carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.87β · 106% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.